Gallipoli Medical Research Foundation, The University of Queensland, Brisbane, Queensland, Australia; Department of Thoracic Medicine, Royal Brisbane & Women's Hospital, Butterfield Street, Herston, Brisbane, Queensland, Australia.
Sunshine Coast Health Institute, Sunshine Coast, Queensland, Australia; University of the Sunshine Coast, Sunshine Coast, Queensland, Australia; Department of Respiratory Medicine, Sunshine Coast University Hospital, 6 Doherty St, Birtinya, Sunshine Coast, Queensland 4575, Australia.
Clin Chest Med. 2023 Dec;44(4):785-798. doi: 10.1016/j.ccm.2023.06.010. Epub 2023 Aug 13.
Mycobacterium abscessus pulmonary disease is highly antibiotic-resistant, and the current armamentarium of antibiotics yields poor treatment outcomes with significant drug toxicity. Macrolide susceptibility is a key prognostic factor. Optimal drug combinations, duration of therapy, and management of refractory disease are unknown. Surgical resection, performed at centers with experience in surgical management of nontuberculous mycobacterial pulmonary disease, may produce favorable outcomes in select patients. Multiple emerging therapeutic candidates hold promise for more efficacious and tolerable treatment options.
脓肿分枝杆菌肺病具有高度的抗生素耐药性，目前的抗生素药物治疗方案疗效不佳，且具有严重的药物毒性。大环内酯类药物敏感性是一个关键的预后因素。最佳的药物组合、治疗持续时间以及难治性疾病的管理尚不清楚。在具有非结核分枝杆菌肺病手术治疗经验的中心进行手术切除，可能会使部分患者获得良好的结果。多种新兴的治疗候选药物有望提供更有效和更耐受的治疗选择。
